

Targets to Therapies (T2T)

2026 Annual Meeting (Virtual)

Time (EST)	Topic
10:00–10:20 AM EST 7:00–7:20 AM PST 3:00–3:20 PM GMT	Welcome & T2T Initiative Overview
10:20–11:35 AM EST 7:20–8:35 AM PST 3:20–4:35 PM GMT	Validation Target Team Deep Dives I: NOD2 and Neuroinflammation Targets <ul style="list-style-type: none"> • Overview of neuroinflammation co-chairs, team & priorities <i>Speakers: Jonathan Behr, Rebecca Senter</i> • NOD2 Project Presentations <ul style="list-style-type: none"> ○ “Characterizing NOD2 Genetic Landscape Driving Risk of Parkinson’s Disease” <i>Speakers: Inga Peter, Towfique Raj, Yuval Itan</i> ○ “Using knowledge graphs to predict NOD2 directionality for therapeutic effect in PD” <i>Speakers: Virginie Buggia Prevot, Sara Bandres Ciga</i> ○ “Development and Validation of Synthetic NOD2 Modulators for Parkinson’s Disease” <i>Speakers: Howard Hang, Hao Wu</i> • Next round of targets & Q&A: TREM2, STING, TLR2 <i>Speaker: Rita Cowell</i>
11:35–11:45 AM EST 8:35–8:45 AM PST 4:35–4:45 PM GMT	Break
11:45 AM–1:15 PM EST 8:45–10:15 AM PST 4:45–6:15 PM GMT	Validation Target Team Deep Dives II: Endolysosomal Targets <ul style="list-style-type: none"> • Introduction to TRPML1, TMEM175 and ATP13A2 <i>Speakers: Stacy Henry</i> • Endolysosomal Target Team Presentations <i>Facilitated by: Magdalene Moran</i> <ul style="list-style-type: none"> ○ In vitro: <i>J. Wade Harper, Peter Vangheluwe, Luis Bonet- Ponce, Christian Grimm, Loren Looger, Monther Abu-Remaileh</i> ○ In vivo: <i>Miratul Muqit, Peter Vangheluwe, Monther Abu-Remaileh Leon Murphy Jacob Eriksen Paul Wes</i> ○ Patient Population: <i>Ziv Gan-Or, Edward Fon Grzegorz Kudla, Tom Grammatopoulos Peter Vangheluwe</i> • Next steps & Q&A <i>Facilitated by: Alastair Reith</i>
1:15–1:25 PM EST 10:15–10:25 AM PST 6:15–6:25 PM GMT	Break
1:25–2:00 PM EST 10:25–11:00 AM PST 6:25–7:00 PM GMT	Validation Target Team Deep Dives III: OGA and Aggregation Targets <ul style="list-style-type: none"> • Overview of OGA <i>Speakers: Hallie Roach (MJFF) & Kalpana Merchant</i> • “Multiscale measurement of O-GlcNAc changes in Parkinson’s Disease” <i>Speakers: Matthew Pratt, Lance Wells, Linda Hsieh-Wilson</i>

Next round of targets and Q&A *Speakers: Hallie Roach (MJFF) & Kalpana Merchant*

Targets to Therapies (T2T) 2026 Annual Meeting (Virtual)

Time (EST)	Topic
10:00–10:30 AM EST 7:00–7:30 AM PST 3:00–3:30 PM GMT	Overview of Prioritization of Symptomatic Outcomes <i>Speakers: Allie Vaiana & Brian Fiske</i>
10:30–10:50 AM EST 7:30–7:50 AM PST 3:30–3:50 PM GMT	Knowledgebase Overview <i>Moderated by: Gaia Skibinski (MJFF)</i> <ul style="list-style-type: none"> Target Explorer: Disease modification and symptomatic targets <i>Speaker Anthony Bosshardt</i> Demo of Agentic Workflow for target prioritization <i>Speakers: Greg Minevich, Kexin Huang</i>
10:50–11:00 AM EST 7:50–8:00 AM PST 3:50–4:00 PM GMT	T2T Tools Overview <i>Speaker Nicole Polinski (MJFF)</i>
11:00–11:10 AM EST 8:00–8:10 AM PST 4:00–4:10 PM GMT	Break & Transition to Breakout Rooms
11:10 AM–2:30 PM EST 8:10–11:30 AM PST 4:10–7:30 PM GMT	Breakout Session 1: Neuroinflammation Targets (<i>Lead: Gaia Skibinski, MJFF</i>) Breakout Session 2: Endolysosomal Targets (<i>Lead: Shalini Padmanabhan, MJFF</i>) Breakout Session 3: Aggregation Targets (<i>Lead: Hallie Roach, MJFF</i>) Breakout Session 4: Mitochondria and Neuroprotective Targets (<i>Lead: Allie Vaiana, MJFF</i>)